ClinicalTrials.gg
CompletedNCT02183051Updated Jul 8, 2014

Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar

A Phase 2 interventional study of Meloxicam 7.5 mg and Meloxicam 3.75 mg in Pain, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
381
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing meloxicam in Pain — 1 open to participants now, 1 under way, none of them phase 3. Meloxicam · Pain.

Enrollment
2nd of 10
381 · median 210
Started
1998
the only one that year
Phase 2
2 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
1 of 10
Boehringer Ingelheim

Among the 10 studies testing meloxicam in Pain, this one is the 2nd largest by enrollment, is the only one that started in 1998, is one of 2 in phase 2, and was the 1st registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

1 of the 10 studies testing meloxicam in Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About meloxicam

Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing meloxicam in Pain, or all of them as a file.
02

Study summary

To assess the analgesic efficacy and tolerability of meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg oral (rapid release tablet) compared with placebo and ibuprofen 400 mg and 200 mg administered in a single dose, over an observation period of 6 hours in the treatment of pain after surgery of the third molar.

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 years or above
  • Patients undergoing removal of one impacted mandibular third molar under local anesthesia. (Short duration anaesthetics will be allowed, i.e. mepivacaine 3% in Italy and Spain and xylocaine in USA, both without vasoconstrictors) Only patients with type of inclusion II to IV have to be included (type II, molar in the submucosa; type III, molar partially included in the bone; type IV, molar fully included in the bone)
  • Assessment of pain must be at least 50 mm on a 100 mm visual analogue scale (VAS)
  • Patient in accordance with local legislation.

Exclusion criteria

Exclusion Criteria:

  • Type I of inclusion (molar partially or totally erupted)
  • Known or suspected to trial drug or their , analgesics, antipyretics or nonsteroidal antiinflammatory drug (NSAIDs)
  • Any clinical evidence of active peptic ulceration during the last six month
  • Recurrent ulcers
  • Pregnancy or breast feeding
  • Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs
  • Concomitant treatment with anti-coagulants (including heparin), lithium
  • Concomitant administration of other anti inflammatory or analgesic agents
  • Administration of any drug with analgesic properties in the 24 h previous to the administration of the study drug, except the local anesthetic for the surgery
  • Administration of any antibiotics
  • Significant perioperative complication judged by the oral surgeon
  • Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, hematological disease (including bleeding disorders), mental disturbance, ulcerative colitis
  • Any other disease that could interfere with the evaluation of efficacy and safety
  • Participation in another clinical trial during this study or during the previous month
  • Previous participation in this trial
  • Patient unable to comply with the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
381 participants (actual)

Study arms

  • Experimental
    Meloxicam 15 mg

    Drug: Placebo · Drug: Meloxicam 15 mg

  • Experimental
    Meloxicam 7.5 mg

    Drug: Meloxicam 7.5 mg · Drug: Placebo

  • Experimental
    Meloxicam 3.75 mg

    Drug: Meloxicam 3.75 mg · Drug: Placebo

  • Experimental
    Meloxicam 1.875 mg

    Drug: Meloxicam 1.875 mg · Drug: Placebo

  • Active comparator
    Ibuprofen 400 mg

    Drug: Placebo · Drug: Ibuprofen 400 mg

  • Active comparator
    Ibuprofen 200 mg

    Drug: Ibuprofen 200 mg · Drug: Placebo

  • Placebo comparator
    Placebo

    Drug: Placebo

06

What researchers measure

Primary outcomes

  1. Assessment of pain intensity differences (PID) on a visual analogue scale (VAS, 100 mm) from one hour onwards

    Time frame: 60, 90, 120, 180, 240, 300 and 360 minutes after drug administration

Secondary outcomes

  1. Assessment of PID on a VAS

    Time frame: Up to 360 minutes after drug administration

  2. Sum of pain intensity differences (SPID)

    Time frame: Up to 360 minutes after drug administration

  3. Number of patients with pain decrease >=50%

    Time frame: Up to 360 minutes after drug administration

  4. Assessment of maximum pain decrease on a VAS

    Time frame: Up to 360 minutes after drug administration

  5. Number of withdrawals due to safety reasons

    Time frame: Up to 7 days after drug administration

  6. Number, nature and severity of adverse events

    Time frame: Up to 7 days after drug administration

  7. Total pain relief (TOTPAR) assessed by patient (Area under the pain relief-by time curve)

    Time frame: Up to 360 minutes after drug administration

  8. Assessment of onset of analgesic action

    Time frame: Up to 2 hours after surgery

  9. Final assessment of efficacy by patient on a 4-point verbal rating scale (VRS)

    Time frame: 6 hours after drug administration

  10. Final assessment of efficacy by investigator on a 4-point VRS

    Time frame: 2 hours after drug administration

  11. Change from baseline in laboratory values

    Time frame: Baseline, up to 7 days after drug administration

  12. Assessment of the progress of healing of the extraction site

    Time frame: 3-7 days after drug administration

  13. Patient's assessment of overall tolerability on a 4-point rating scale

    Time frame: Day 7 after drug administration

  14. Investigator's assessment of overall tolerability on a 4-point rating scale

    Time frame: Day 7 after drug administration

  15. Pain relief assessed by patient on a 5-point VRS

    Time frame: Up to 360 minutesafter drug administration

  16. Number of withdrawals due to inadequate efficacy

    Time frame: Up to 7 days after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1998 and a primary completion of Oct 1998. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Apr 1998
Primary completionActual
Oct 1998
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183051
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Apr 1998
Primary completion
Oct 1998
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meloxicam · Ibuprofen

Start the discussion